The relationship between aggregation and toxicity of polyglutamine-containing ataxin-3 in the intracellular environment of Escherichia coli

PLoS One. 2012;7(12):e51890. doi: 10.1371/journal.pone.0051890. Epub 2012 Dec 14.

Abstract

Several neurodegenerative diseases are triggered by proteins containing a polyglutamine (polyQ) stretch expanded beyond a critical threshold. Among these, ataxin-3 (AT3) is the causative agent of spinocerebellar ataxia type-3. We expressed three authentic AT3 variants in Escherichia coli: one normal (AT3-Q24), one expanded (AT3-Q55) and one truncated immediately upstream of the polyQ (AT3-291Δ). Then, based on growth rate reduction, we quantified protein toxicity. We show that AT3-Q55 and -291Δ strongly reduced the growth rate in the early stages (2-4 h), unlike AT3-Q24. This correlated well with the appearance of soluble cytosolic oligomers, but not with the amount of insoluble protein in inclusion bodies (IBs). The impact of AT3-291Δ on cell growth suggests an intrinsic toxicity of the AT3 fragment. Besides the typical Fourier Transform Infrared Spectroscopy (FTIR) signal for intermolecular β-sheets, the expanded form displayed an additional infrared signature, which was assigned to glutamine side-chain hydrogen bonding and associated with SDS-insoluble fibrils. The elongation of the latter was monitored by Atomic Force Microscopy (AFM). This mirrors the well-known in vitro two-step aggregation pattern of expanded AT3. We also demonstrated that final aggregates of strains expressing expanded or truncated AT3 play a protective role against toxicity. Furthermore, our findings suggest that the mechanisms of toxicity are evolutionarily conserved.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Escherichia coli / genetics
  • Escherichia coli / metabolism*
  • Hydrogen Bonding
  • Inclusion Bodies / chemistry
  • Inclusion Bodies / metabolism
  • Nerve Tissue Proteins / chemistry*
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism*
  • Nuclear Proteins / chemistry*
  • Nuclear Proteins / genetics
  • Nuclear Proteins / metabolism*
  • Peptides / chemistry*
  • Peptides / metabolism*
  • Protein Structure, Secondary

Substances

  • Nerve Tissue Proteins
  • Nuclear Proteins
  • Peptides
  • polyglutamine

Grants and funding

This work was supported by the following: Fondazione Cariplo (N.O.B.E.L. project); Italian Ministry for Instruction, University and Research, PRIN 2007 project n. 2007XY59ZJ_004; Regione Lombardia (Network Enabled Drug Design); A.N. and G.I. acknowledge postdoctoral fellowships of the University of Milano-Bicocca. This work was partially supported by University of Genoa (Progetti di Ateneo). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.